SHASUNPHAR

Shasun Pharmaceuticals Limited has informed the Exchange, vide letter dated June 28, 2013 that "An amicable settlement has been reached with the workers at the Company's Pondicherry facility. The strike has been called off and operations resumed from yesterday night".

Cholamandalam Investment and Finance Company Ltd has submitted to the Exchange vide letter dated June 20, 2013 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange that an illegal strike was resorted by the workers at the Company's Pondicherry facility (API and Formulation) on June 15, 2013. The Company is doing needful to resume the operations at the earliest.

Shasun Pharmaceuticals Limited has informed the Exchange that the Company has fixed Book Closure from July 25, 2013 to August 2, 2013 (both days inclusive) for the purpose of dividend. Further, the Annual General Meeting (AGM) of the Company will be held on August 02, 2013.

Shasun Pharmaceuticals Limited has informed the Exchange that the Dividend payment will be between August 09, 2013 and August 14, 2013.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 29, 2013 has recommended a dividend of 75% (Rs.1.50 per share) on the equity shares of face value of Rs.2/- each, subject to shareholders approval at ensuing Annual General Meeting.

Shasun Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2013.

D Sajjan has submitted to the Exchange vide its letter dated May 15, 2013 a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a Press Release dated April 10, 2013, titled "Shasun Pharmaceuticals Ltd and Debiopharm Group(TM) enter into licensing agreement for the manufacturing and commercialization of Huperzine-A".

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on March 21, 2013 has approved the conversion of 15,00,000 convertible warrants into equity shares of the Company, which were issued to the promoters and directors on preferential basis at a price of Rs. 75 per share including premium of Rs. 73 per share after obtaining the in-principle approvals from the stock exchanges.

D Sajjan has submitted to the Exchange vide its letter dated February 15, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

D. Sajjan has submitted to the Exchange vide letter dated February 08, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with the Limited Review Report for the period ended December 31,2012.

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of letter from the Company's Managing Director dated January 29, 2013 to be sent to the Company's Shareholders.

Shasun Pharmaceuticals Limited has submitted to the Exchange, vide letter dated December 24, 2012 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Sundaram Asset Management Company Limited has submitted to the Exchange vide letter dated December 24, 2012 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange vide letter dated December 21, 2012 regarding the Results of the Postal Ballot.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a Notice pursuant to Section 192A of the Companies Act, 1956, read with the Companies (Passing of the Resolution by Postal Ballot), Rules, 2011 to transact the business mentioned in the notice as Special Resolution by the Members of Shasun Pharmaceuticals Limited by means of Postal Ballot .

D Sajjan has submitted to the Exchange vide its letter dated November 15, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with the Limited Review Report for the period ended September 30,2012.

V. Leela has submitted to the Exchange vide letter dated September 30, 2012 a copy of disclosure under Regulation 31(1), 31(2),31(3) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Devendra Estates Private Limited has submitted to the Exchange vide letter dated September 30, 2012 a copy of disclosure under Regulation 31(1), 31(2),31(3) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

D. Sajjan has submitted to the Exchange vide letter dated September 06, 2012 a copy of disclosure under Regulation 31(1) & 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sundaram Asset Management Company Limited has submitted to the Exchange vide letter dated August 21, 2012 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has submitted to the Exchange vide its letter dated August 13, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Citibank N.A. has submitted to the Exchange vide its letter dated August 10, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange vide letter dated August 07, 2012 regarding the Outcome of the Annual General Meeting of the Company held on August 02, 2012 and Voting Results as per Clause 35A of the Listing Agreement.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on August 02, 2012 have appointed Ms. Indira J Parikh as Independent Director of the Company.

Shasun Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with the Limited Review Report for the period ended June 30,2012.

S. Devendra has submitted to the Exchange vide letter dated July 26, 2012 a copy of disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange that the dividend payment will be between August 09, 2012 and August 14, 2012.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors at their meeting held on May 24,2012 have decided to close the Share Transfer Books / Register of Members of the Company from July 25, 2012 to August 02, 2012 (both days inclusive) for the purpose of final dividend. The Annual General Meeting of the Company will be held on August 02, 2012.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 24, 2012 has recommended a final dividend of 20% (Rs. 0.40ps per share) on the equity shares of face value of Rs. 2/- each, subject to Shareholders approval at ensuing Annual General Meeting.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 24, 2012, titled "Shasun announces Year ended 31st March 12 Results: Shasun achieved sales of Rs 1066 Crores and PAT of Rs 101 Crores in FY 12".

Shasun Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2012.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 18, 2012, titled "Shasun turnover crosses Rs.1000 crores as it celebrates its 35 years of service to the pharmaceutical industry".

Caduceus Asia Mauritius Limited has submitted to the Exchange vide its letter dated March 30, 2012 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board at its meeting held on March 29, 2012 allotted 65,78,947 equity shares to M/s. Caduceus Asia Mauritius Limited, Mauritius. The Company also appointed Dr. Sunny Sharma nominee of M/s. Caduceus Asia Mauritius Ltd as an Additional Director of the Company.

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of the minutes of the Extra Ordinary General Meeting of the Company held on March 22, 2012.

Shasun Pharmaceuticals Limited has informed the Exchange that pursuant to Shareholders' approval on July 29, 2011, the Company has concluded the sale of its Velachery property for a gross consideration of Rs.29 Crores.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on March 15, 2012 approved an Interim Dividend of 100% (Rs.2/- per share) on the equity shares of face value of Rs.2/- each.

Shasun Pharmaceuticals Limited has informed the Exchange that March 22, 2012 has been Fixed as a Record Date for the purpose of Interim Dividend for 2011-12.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 27, 2012, decided to issue and allot up to 65,78,947 equity shares of the Face value of Rs. 2/- for cash at a price of Rs. 76/- per share (including a premium of Rs. 74/- per share) aggregating to about Rs. 50 crores, being the price not less than the price determined in accordance with the SEBI Guidelines, to M/s. Caduceus Asia Mauritius Limited, a Company incorporated under the laws of Republic of Mauritius and having its registered office at 608, St James Court

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of letter from the Company's Managing Director dated February 21, 2012 to be sent to the Company's Shareholders.

Shasun Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with the Limited Review Report for the period ended December 31,2011.

Shasun Pharmaceuticals Limited has informed the Exchange that the operations has resumed at the Company's Cuddalore plant on January 05, 2012.

Cholamandalam Investment and Finance Company Limited has submitted to the Exchange a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange that the operations at Cuddalore plant of the Company has been interrupted due to severe cyclonic storm "Thane" on December 30, 2011, resulting in temporary suspension of the operations. The Company is doing needful to resume the operations at the earliest.

V.Leela has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1),31(2),31(3) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

A. Deepak has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.